Teinture Menopausix
Natural health product licensed in Canada
- Licence holder
- Clef des Champs Inc.
- NPN or DIN-HM
- 80028971
- Status
- Active licence
- Licence date
- 11 January 2012
- Revision date
- 3 September 2024
- Form
- Teinture
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Leonurus cardiaca L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les femmes enceintes
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Zingiber officinale Source : Rhizome(s) Extraction ratio : 1:2.1 Dry plant equivalent : 34 mg | 0.07 mL | Not calculated |
| Leonurus cardiaca Source : Parties aériennes Extraction ratio : 1:2.2 Dry plant equivalent : 32 mg | 0.07 mL | Not calculated |
| Viburnum opulus Source : Écorce Extraction ratio : 1:3.3 Dry plant equivalent : 45 mg | 0.15 mL | Not calculated |
| Panax quinquefolius Source : Racine Extraction ratio : 1:6.7 Dry plant equivalent : 5 mg | 0.03 mL | Not calculated |
Non-medicinal ingredients
Éthanol
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | maximum: 2 mL | maximum: 3 days |
Uses authorised in Canada
Utilisé en herboristerie occidentale pour aider à soulager les symptômes de la ménopause.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consulter un praticien de la santé si vous souffrez de troubles de foie. Consulter un praticien de la santé si les symptômes persistent ou s'aggravent. Consulter un praticien de la santé pour un usage de plus d'un an. Éviter la prise simultanée de médicaments d'ordonnance.
- Contre-indications
Ne pas utiliser en cas de grossesse, tentative de grossesse ou allaitement. Consulter un praticien de la santé si vous souffrez de troubles du foie, si les symptômes persistent, s’aggravent ou avant d’en faire un usage prolongé. Éviter la prise simultanée de médicaments d’ordonnance.
Source
Official Health Canada record, licence 80028971
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging